Home > Heart Failure
    Content Type:
  • Heart Failure


    An Introduction to Heart Failure

    Much progress has been made in the management of heart failure in patients with reduced ejection fraction (HFrEF) and the development of therapies for HF with preserved ejection fraction is ongoing. Promising new therapeutics in HF include a dual-acting angiotensin receptor-neprilysin inhibitor, soluble guanylate cyclase (sGC) stimulator and a cardiac myosin activator. It is hoped that gene therapy will be available for patients with HFrEF in the near future.

    Browse the content below where leading experts discuss the latest data in video interviews and short articles from our conference hub, and browse the selection of peer- reviewed articles from our journal portfolio.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Heart Failure Content

    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar